• Wei Ye, Min Yao, Yangchao Dong, Chuantao Ye, Dan Wang, He Liu, Hongwei Ma, Hui Zhang, Libin Qi, Yuewu Yang, Yuan Wang, Liang Zhang, Linfeng Cheng, Xin Lv, Zhikai Xu, Yingfeng Lei, and Fanglin Zhang.
• Department of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
• Front Microbiol. 2020 Jan 1; 11: 1105.

AbstractHuman enteroviruses are responsible for diverse diseases, from mild respiratory symptoms to fatal neurological complications. Currently, no registered antivirals have been approved for clinical therapy. Thus, a therapeutic agent for the enterovirus-related disease is urgently needed. Remdesivir (GS-5734) is a novel monophosphoramidate adenosine analog prodrug that exhibits potent antiviral activity against diverse RNA virus families, including positive-sense Coronaviridae and Flaviviridae and negative-sense Filoviridae, Paramyxoviridae, and Pneumoviridae. Currently, remdesivir is under phase 3 clinical development for disease COVID-19 treatment. Here, we found that remdesivir impeded both EV71 viral RNA (vRNA) and complementary (cRNA) synthesis, indicating that EV71 replication is inhibited by the triphosphate (TP) form of remdesivir. Moreover, remdesivir showed potent antiviral activity against diverse enteroviruses. These data extend the remdesivir antiviral activity to enteroviruses and indicate that remdesivir is a promising antiviral treatment for EV71 and other enterovirus infections.Copyright © 2020 Ye, Yao, Dong, Ye, Wang, Liu, Ma, Zhang, Qi, Yang, Wang, Zhang, Cheng, Lv, Xu, Lei and Zhang.

6 keywords...

hide…